Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4105439
Max Phase: Preclinical
Molecular Formula: C38H40ClN3O5
Molecular Weight: 654.21
Molecule Type: Small molecule
Associated Items:
ID: ALA4105439
Max Phase: Preclinical
Molecular Formula: C38H40ClN3O5
Molecular Weight: 654.21
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)c1cc(Cl)ccc1OCc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C=O)Cc1ccccc1
Standard InChI: InChI=1S/C38H40ClN3O5/c1-26(2)20-33(41-36(44)32-23-30(39)18-19-35(32)47-25-29-16-10-5-11-17-29)38(46)42-34(22-28-14-8-4-9-15-28)37(45)40-31(24-43)21-27-12-6-3-7-13-27/h3-19,23-24,26,31,33-34H,20-22,25H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)/t31-,33-,34-/m0/s1
Standard InChI Key: JXLRSGZBTMKOCD-XLDNGHKCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 654.21 | Molecular Weight (Monoisotopic): 653.2656 | AlogP: 5.72 | #Rotatable Bonds: 16 |
Polar Surface Area: 113.60 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.04 | CX Basic pKa: | CX LogP: 6.60 | CX LogD: 6.60 |
Aromatic Rings: 4 | Heavy Atoms: 47 | QED Weighted: 0.13 | Np Likeness Score: -0.28 |
1. Jorda R, Dušek J, Řezníčková E, Pauk K, Magar PP, Imramovský A, Kryštof V.. (2017) Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine., 135 [PMID:28441582] [10.1016/j.ejmech.2017.04.027] |
Source(1):